CXCR4 blocking has been evaluated in several clinical trials as a strategy to reduce cancer development, but since this chemokine is abundantly expressed at both tumor and non-tumor sites, CXCR4 blockade specifically in tumors can be difficult. Here, CXCR4 is linked to cancer.